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Abstract 
Bone morphogenetic protein (BMP) 2-incorporated gelatin sponge is effective for in 
vivo osteoinduction. However, the modeling capacity of bone decreases with age. As a 
trial to stimulate effective bone formation for animals with decreased osteogenic 
potential, Wnt1 inducible signaling pathway protein (WISP) 1, an osteoblastic regulator, 
was combined with gelatin sponge incorporating BMP2. Osteopontin (Opn) gene 
expression was increased in vitro for mouse bone marrow stromal cells (BMSC) 
cultured in gelatin sponges incorporating BMP2 and WISP1 compared with those 
incorporating BMP2 or WISP1 alone. In vivo synergistic effect of BMP2 and WISP1 on 
the ectopic osteoid formation was observed when gelatin sponges incorporating BMP2 
and WISP1 were implanted subcutaneously into middle-aged mice with decreased bone 
formation potential. It is concluded that the scaffold incorporating multiple 
osteoinductive agents could be effective in inducing bone formation in those with 
age-related decreased potential of bone formation. 
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1. Introduction 
It is well known that bone formation is impaired with aging [1, 2]. The bone is 
composed of extracellular matrix proteins, including type I collagen, stiffened by the 
crystals of calcium hydroxyapatite, and bone loses its matrix and mineral composition 
with advancing age [1, 3]. At the cellular level, bone formation is a function of the 
osteoblast cell lineage, whereas bone resorption is regulated by cells of the osteoclast 
linage [4, 5]. It has been also reported that aging is accompanied by the alteration of the 
relationship between osteoblasts and osteoclasts [6, 7]. In the rat model of ectopic bone 
formation, bone tissue induced ectopically by the subcutaneous implantation of BMP2 
into rat back skin was reduced with increasing age [8]. 
 The bone morphogenetic protein (BMP) 2 incorporated in porous 
biodegradable scaffold is useful for bone tissue engineering. BMP subfamily within the 
transforming growth factor- (TGF-) superfamily is a group of proteins with 
osteoinductive activity [9, 10]. Among the BMP subfamilies, BMP2 was originally 
cloned from the bovine bone [11]. It has been also shown that recombinant human 
BMP2 induces ectopic bone formation in rats [12]. The advantage of BMP2 in bone 
tissue engineering is to the clinical application for bone regeneration at the bone defect 
[13]. It has been demonstrated that a biodegradable hydrogel of gelatin is used for the 
controlled release of BMP2 [14]. Generally, the direct injection of growth factor 
solution into the site to be regenerated is not therapeutically effective. This is because 
the water-soluble factors are rapidly excreted from the injected site and often digested 
or deactivated. BMP2 was retained in the gelatin hydrogel in vivo for more than 1 
month and long-termed BMP2 release was achieved [14]. BMP2-incorporated 
three-dimensional porous structure of gelatin hydrogel, what has been referred to as 
“gelatin sponges”, is effective for osteoinduction both in vitro and in vivo [15, 16].  
As one of the trials to stimulate effective bone formation in the patients with 
decreased osteogenic potential, bone tissue engineering approach to combine scaffold 
with multiple osteoinductive agents is worth examining. Wnt signaling pathway is 
predicted to control bone mass because of the increased bone mass in human with 
mutations in the Wnt receptor low density lipoprotein receptor-related protein (LRP) 5/6 
[17, 18]. Wnt1 inducible signaling pathway protein 1 (WISP1; also known as CCN4) is 
a member of CCN family protein, originally cloned as the target gene of the 
Wnt1/Frizzled pathway in the breast cancer cells [19]. It has been shown that 
recombinant WISP1 promotes proliferation and osteogenic differentiation of human 
bone marrow stromal cells (BMSC) in vitro [20]. Interestingly, human BMSC 
co-transduced WISP1 and BMP2 had significantly greater ectopic bone formation than 
those transduced with BMP2 alone when implanted into the back of mice [20]. 
In this study, both BMP2 and WISP1 were incorporated into gelatin sponges, 
and the in vitro osteogenic activities of gelatin sponges incorporating BMP2 and/or 
WISP1 were investigated. Ectopic bone formation in vivo was investigated by the 
subcutaneous implantation of gelatin sponges incorporating BMP2 and/or WISP1 into 
mice of a middle age, in which the bone formation activity declines, and compared with 
that of sponges incorporating BMP2 or WISP1. 
 
2. Materials and Methods 
2.1. Materials 
A gelatin sample with an isoelectric point (IEP) of 9.0 was prepared through an acidic 
process of porcine skin collagen type I (Nitta Gelatin Co., Osaka, Japan). β-tricalcium 
phosphate  (β-TCP) granules (2 µm in average diameter) were obtained from Taihei 
Chemical Industries, Nara, Japan. Na125I (740MBq/ml in 0.1N NaOH aqueous solution) 
was purchased from Du Pont NEN Research Products (Wilmington, MA, USA). 
Glutaraldehyde (GA), glycine, and other chemicals were obtained from Wako Pure 
Chemical Industries, Ltd. (Osaka, Japan) and used without further purification. The 
monoclonal antibodies 30-F11 (anti-CD45) and D7 (anti-Sca-1) were from eBioscience, 
Inc. (San Diego, CA, USA). All primers (Table 1), SuperScript VILO and Dulbecco's 
Modified Eagle's Medium (DMEM) were purchased from Invitrogen Corporation 
(Carlsbad, USA). RNeasy Plus Mini Kit was from Qiagen Inc. (Valencia, CA). Power 
SYBR Green PCR Master Mix was purchased from Applied Biosystems (Foster City, 
CA). Fetal bovine serums (FBS) were purchased from Hyclone (Logan, UT, USA). 
Propidium iodide was obtained from Dojindo Laboratories (Kumamoto, Japan). 2.4G2 
hybridoma was purchased from American Type Culture Collection (Rockville, MD, 
USA). WISP1 was purchased from PeproTech (Rocky Hill, NJ, USA) .  
 
2.2. Mice 
C57BL/6NCrSlc female mice were purchased at 4-12 weeks old from Shimizu 
Laboratory Supplies Co. (Kyoto, Japan) and were used between 6 and 38 weeks old. All 
animal experimentation was conducted in accordance with the guidance of the Institute 
for Frontier Medical Sciences, Kyoto University. 
 
2.3. Preparation of gelatin sponges with β-TCP 
Gelatin sponges incorporating β-TCP were prepared as described previously [15]. 
Briefly, 4.29 wt% aqueous solution of gelatin (70 ml) was mixed at 5000 rpm at 37◦C 
for 3 min by using a homogenizer (ED-12, Nihonseiki Co., Tokyo, Japan). After 
addition of and 10 wt% of β-TCP and 2.17 wt% of glutaraldehyde aqueous solution (30 
ml), the mixed solution was further mixed for 15 s by the homogenizer. The resulting 
solution was cast into a polypropylene dish of 138 x 138 mm2 and 5 mm depth, 
followed by leaving at 4◦C  for 12 hr for gelatin crosslinking. Then, the cross-linked 
gelatin hydrogels with β-TCP were placed into 100 mM of aqueous glycine solution at 
37◦C for 1 hr to block the residual aldehyde groups of glutaraldehyde. Following 
complete washing with double distilled water (DDW), the hydrogels were freeze-dried 
and cut into disks (5 mm diameter). 
 
2.4. In vitro release study of BMP2 and WISP1 from gelatin sponges 
BMP2 and WISP1 were radioiodinated through the conventional chloramine-T method 
as previously described [21]. Briefly, 5 ml of Na125I was added to 50 µl of 5 mg/ml 
BMP2 or 1 mg/ml WISP1 solution in 0.5 M potassium phosphate buffer (pH 7.5) 
containing 0.5 M NaCl. Then, 0.2 mg/ml chloramine-T in the same buffer (100 µl) was 
added to each solution mixture. After agitation at room temperature for 2 min, 100 µl of 
phosphate-buffered saline (PBS) solution (pH 7.5) containing 0.4 mg sodium 
metabisulfate was added to the reaction solution to stop the radioiodination. The 
reaction mixtures were passed through PD-10 columns to remove the uncoupled, free 
125I molecules from the 125I-labeled BMP2 and WISP1. A PBS solution of 125I-labeled 
BMP2 and/or WISP1 (20 µl) was dropped onto the freeze-dried sponges of gelatin (5 
mm diameter), followed by leaving at 25◦C  for 3 h to obtain hydrogel sponges 
incorporating 125I-labeled BMP2, WISP1, or both. For the in vitro release test, hydrogels 
incorporating 125I-labeled cytokines were agitated at 37◦C  in 1 ml of PBS. The 
supernatant was removed 1, 2, 4, 6, 12, and 24 h later and replaced with the same 
volume of fresh PBS. The radioactivity of each supernatant was measured on a gamma 
counter (ARC-301B, Aloka, Tokyo, Japan) to evaluate the time profile of cytokines 
release (n = 3 at each time point). 
 
2.5. In vitro culture of BMSC in gelatin sponges 
To isolate BMSC, fresh bone marrow cells were harvested from femurs and tibias of the 
euthanized mice (7 wk old), and were suspended in DMEM supplemented with 2% FBS 
and penicillin/streptomycin. The red blood cells were hemolyzed in BD Pharm Lyse 
Lysing Buffer (BD Bioscience, Rockville, MD, USA) under the manufacturer's 
guidance. The cell suspensions were filtered through a cell strainer (BD Bioscience) to 
remove debris. The filtrates were pelleted by centrifugation for 5 min at 4 ◦C. The bone 
marrow cells were resuspended at 5 x 106 cells/ml in DMEM supplemented with 10% 
FBS and penicillin/streptomycin, and plated onto 100-mm culture dish. The adherent 
cells were passaged two times before use. 
 The BMSC at passage two were incubated with 1 ml of the 0.25% 
trypsin/EDTA solution for 5 min at 37◦C, until the cells detach from the dishes. The 
cells were washed by centrifugation, and seeded onto the gelatin sponges in which 
BMP2 and/or Wips1 were incorporated as described above. BMSC were resuspended in 
DMEM supplemented with 10% FBS, 50 µg/ml ascorbic acid-2- phosphate , 10 mM 
β-glycerophosphate, 10-8 M dexamethasone. The cell suspensions were seeded into the 
gelatin sponges by an agitated seeding method, by which cells were seeded 
homogeneously throughout 3-dimensional porous scaffolds [15]. 
 
2.6. Quantitative, real-time polymerase chain reaction with reverse transcription 
(qRT-PCR)  
The total RNA was extracted from BMSC cultured for 7 days in gelatin sponges 
incorporating BMP2 and/or Wips1 by using RNeasy Kit according to the manufacturers’ 
instructions. Reverse transcription reaction was performed with SuperScript VILO. 
Real-time PCR was performed on a Prism 7500 real-time PCR thermal cycler (Applied 
Biosystems, Foster City, CA, USA) from 10 ng of cDNA in a total volume of 25 ml 
containing Power SYBR Green PCR Master Mix and 10 mM of each primer (Table 1). 
The reaction mixture was incubated for the initial denaturation at 95◦C for 10 min, 
followed by 40 PCR cycles. Each cycle consisted of the following three steps; 94◦C for 
15 s, 57◦C for 15 s  and 72◦C for 1 min. Each mRNA level was normalized by the 
expression level of 18S ribosomal RNA as an internal control (n = 3 at each treatment 
combination). 
 
2.7. In vivo osteogenic ectopic assay 
Gelatin hydrogels incorporating BMP2 and/or WISP1 as described above were 
implanted into the back subcutis of mice at various ages (6 mice/experimental group). 
The BMP2-free, WISP1-free empty gelatin hydrogel were used as controls. The skin 
tissue including the hydrogel-implanted or injected site was taken out for following 
flow cytometric and histological assays 10 days later. 
 
2.8. Flow cytometric analysis 
Gelatin implants harvested were digested as described previously (Matsuzaki Stem 
cells). Briefly, Gelatin implants were harvested and digested in a solution containing 
400 U/mL collagenase D (Roche, Basel, Switzerland) for 40 minutes at 37°C. The 
resulting single-cell suspensions were blocked by anti-CD16/32 antibody, washed and 
stained with monoclonal antibodies and its secondary reagents in PBS containing 2 
vol% FBS and 0.1 vol% sodium azide. Propidium iodide was used to distinguish dead 
cells from viable cells. The immunostained cells were analyzed on FACSCanto II flow 
cytometer. Analysis was performed by BD FACSDiva software (BD Bioscience) and 
FLOWJO software (Tree Star, San Carlos, CA). 
 
2.9. Histological evaluation of bone tissue ectopically induced by gelatin implants 
Gelatin implants were fixed in 4% paraformaldehyde and equilibrated in 30% 
sucrose/PBS. Fixed samples were embedded in OCT medium (Sakura) and frozen in 
liquid nitrogen. Sections of undecalcified samples were generated via Kawamoto’s film 
method (Cryofilm transfer kit; FINETEC). The 7 mm thick cryostat sections were and 
stained by hematoxylin and eosin (H&E) to view on an optical microscope (AX-80, 
OLYMPUS, Japan). 
 
2.10. Colony forming unit-fibroblast (CFU-F) assay 
CFU-F assay was performed as described previously (Benedetto AD, J cell science, 
2010). In brief, single cell suspensions from gelatin hydrogel implants were suspended 
in αMEM supplemented with 2% FBS, penicillin and streptomycin using a 18-gauge 
needle, and then filtered through a 70 µm cell strainer (Falcon) to remove debris. The 
resulting bone marrow cell suspensions were rinsed in PBS, resuspended in MSC Basal 
Medium (Stem Cells Technologies) supplemented with MSC Stimulatory Supplement 
(Stem Cells Technologies) and plated for determination of the CFU-F. Non-adherent 
cells were removed by changing medium. After 2 weeks of culture, the cells were fixed 
in ethanol and stained by using Hemacolour Staining Kits (Merck) under the 
manufacturer's guidance. Colonies containing more than 16 cells were counted (n = 4 at 
each treatment combination).  
 
2.11. Statistic analysis 
All the results were expressed as the mean ± standard deviation (SD). Significant 
analysis between the experiment groups was done based on the one-way ANOVA, and 





3.1. Release profiles of BMP2 and WISP1 from gelatin sponges with β-TCP 
Figure 1 shows in vitro release profiles of 125I-labeled BMP2 and/or WISP1 from the 
gelatin sponges. The radioactivity remaining in the gelatin sponges decreased with the 
incubation time, and reached a plateau level 4 hr after incubation. A higher amount of 
BMP2 (>90%) was retained in gelatin sponges 24 hr after incubation, in consistent with 
previous reports [14]. Although the lower amount of WISP1 (approximately 56%) was 
retained in gelatin sponges after 24 hr of incubation, it is highly expected that the 
amount is large enough to induce additive or synergistic effects on ectopic bone 
formation. The decrement patterns were not influenced by the co-incorporation of 
BMP2 and WISP1. 
 
3.2. In vitro activities of gelatin sponges incorporating BMP2 and/or WISP1 
Figure 2 shows qRT-PCR results of mouse BMSC cultured for 7 days in gelatin sponges 
incorporating BMP2 and/or WISP1. Gene expression of runt related transcription 
factor (Runx) 2/core-binding factor alpha (Cbfa) 1, a master regulator of 
osteoblast-specific gene expression, was not significantly affected by co-incorporation 
of BMP2 nor WISP1 at this time point (Figure 2A). In contrast, the expression of 
osteopontin (Opn)/secreted phosphoprotein (Spp) 1, secreted protein of osteoblasts, 
increased in BMSC cultured in gelatin sponges incorporating BMP2 and WISP1 
compared with other incorporation conditions (Figure 2B).  
 
3.3. Time course of cell infiltration into the gelatin sponge implants 
The results of in vitro culture prompted us to evaluate in vivo osteogenic activities of 
gelatin sponges incorporating BMP2 and/or WISP1. Figure 3 shows the temporal 
changes of cell infiltration into the gelatin sponges incorporating BMP2. Infiltration of 
CD45+ hematopoietic cells reached a small peak at the earliest phase, and increased at 
10 days after implantation. In contrast to the CD45+ cells, infiltration of CD45-Sca-1+ 
endothelial and stromal lineage cells [22-24] were detected only 10 days after 
implantation. Based on these data, we focused our analysis on the ectopic bone 
formation and cells recruitment into the site of bone formation at 10 days after 
implantation. 
 
3.4. Age-dependent changes in ectopic bone formation 
Gelatin sponges incorporating BMP2 were implanted subcutaneously into mice with 
various ages, ranging from young to middle-aged. Figure 4 shows the histological 
sections of subcutaneous tissues 10 days after implantation. The histological analysis 
revealed that every BMP2-incorporated gelatin sponge induced osteoid formation 
homogeneously around the sponges (Figure 4A). The porous structure of gelatin sponge 
was surrounded by the ectopically formed osteoid tissue. Younger mice had a 
significantly greater bone formation than older mice (Figures 4A and 4B). 
Ade-dependent decrease of bone area was in good accordance with the previous report 
on rats [8]. 
Figure 5 shows the results of CFU-F assay initiated with the cells from gelatin 
sponges incorporating BMP2 and implanted subcutaneously. After 14 days in culture, 
fibroblast-like colonies containing 10-200 cells were observed (Figure 5A). The number 
of colonies decreased with increasing age (Figure 5B). It is in good correspondence 
with the result of histological section. 
 
3.5. Effect of dual release of BMP2 and WISP1 
From the age-stratified analysis, we chose middle–aged mice, in which the ability to 
induce ectopic bone formation is decreased, to evaluate the effect of dual release of 
BMP2 and WISP1. Figures 6A and 6B shows the histological analysis results of gelatin 
sponges incorporating BMP2 and/or WISP1. Ectopic osteoid formation was not 
observed by the implantation of gelatin sponges incorporating only WISP1 (Figures 6A 
and 6B). The areas of osteoid tissues were significantly increased in the site of 
implantation of gelatin sponges incorporating both BMP2 and WISP1, compared with 
that incorporating only BMP2 (Figures 6A and 6B). On the other hand, we observed an 
increase in the number of fibroblastic colonies (CFU-Fs) to lesser extent than observed 
in histological analysis (Figure 6C). 
 
4. Discussion 
Our results demonstrated that the dual release of BMP2 and WISP1 has potential to 
improve ectopic bone formation in mice with decreased ability to induce ectopic bone 
formation. The gelatin sponge incorporating β-TCP was prepared as a release carrier for 
BMP2 and/or WISP1. In vitro, Opn expression increased for BMSC cultured with 
gelatin sponges incorporating BMP2 and WISP1 compared with that of other groups. 
Moreover, the ectopic osteoid formation was enhanced by the implantation of gelatin 
sponges incorporating BMP2 and WISP1 in middle-aged mice.  
We used gelatin hydrogel with porous structure incorporating β-TCP, i.e. 
gelatin sponge, as the release carrier. Biosafety of biodegradable gelatin has been 
proven through its long clinical usage as a plasma expander, in surgical biomaterials and 
as an ingredient in drugs [25]. Our previous study demonstrates that gelatin hydrogel 
incorporating BMP2 have the in vivo osteoinductive activity [14]. The porous structure 
of gelatin hydrogels allowed for cell infiltration, and the incorporation of β-TCP 
improvee the mechanical strength of porous gelatin sponges [15, 16]. In the present 
study, homogeneous osteoid formation around the implant was observed by using 
gelatin sponges incorporating BMP2 in all ages of mice tested (6 – 38 wk). Thus we 
believe that βTCP-reinforced gelatin sponges incorporating BMP2 is one of the useful 
tools to induce ectopic bone formation. In this system, the correlation between the 
gelatin degradation and BMP-2 release was observed, which indicates that BMP2 is 
released from the gelatin sponge based on the in vivo degradation of gelatin [15, 16]. In 
the in vitro release study, severe burst release of WISP1 from the gelatin sponge was not 
observed. It is conceivable that WISP1 remaining in gelatin hydrogel was released as 
the result of the hydrogel degradation in vivo. 
 In this study, the basic-type gelatin (isoelectric point [IEP] = 9.0) was used as 
the carrier material for BMP2 and/or WISP1 release. The electric nature of gelatin can 
be changed by the collagen processing method, and the acidic process yields basic 
gelatin with an IEP of 9.0 [25]. The basic gelatin is preferable as the carrier for acidic 
proteins release, while the acidic gelatin is applicable to the sustained release of basic 
proteins. However, WISP1 has an IEP of 9.2 and is slightly positively charged at the 
physiological pH [26]. Relatively lower amount of WISP1 retained in in vitro release 
study may be explained by the electric nature of WISP1 and gelatin. For better 
osteoinduction, combination of BMP2-incorporated basic gelatin and 
WISP1-incorporated acidic gelatin may improve WISP1 release profile and 
consequently the synergistic effect of BMP2 and WISP1.  
 The CCN family consists of six distinct proteins (i.e. cysteine-rich 61; 
Cyr61/CCN1, CTGF/CCN2, nephroblastoma overexpressed; Nov/CCN3, WISP1, 2, 
and 3; and WISP1–3/CCN4–6). It has been demonstrated that CCN family proteins 
contribute to biological processes in development, tissue repair, and tumor suppression, 
but their exact functions are still unspecified [27]. It has been reported that WISP1 
enhanced the ability of BMP2 to direct BMSC toward osteogenic differentiation in vivo 
and in vitro. Human BMSC transduced with WISP1- and BMP2-adenovirus in a 
combinational fashion expressed significantly high levels of osteogenic markers 
including Opn in vitro, and induced ectopic bone formation when implanted under the 
skin of immunocompromised mice [20]. Our results of Opn gene expression and ectopic 
osteoid formation are comparable to this report. It has been shown that WISP1 bound 
directly to BMP2 and that WISP1 increased BMP2 binding to BMSC [20]. Taken 
together, it is likely that WISP1 enhance the effect of BMP2-induced osteoid formation 
by mesenchymal cells recruited into the site of ectopic osteoid formation. 
 It is well known that, during osteogenesis, Runx2 works as a multifunctional 
transcription factor that controls the expression of various extracellular matrix protein 
genes including Opn, integrin binding sialoprotein (IBSP), and collagen type I [28]. At 
the time point checked in this study, there was no significant effect on Runx2 expression 
for BMSC cultured in gelatin sponges incorporating BMP2 and WISP1 compared with 
that in other sponges, even though the Opn expression increased. Since Runx2 works at 
an early phase of osteogenesis, it is necessary to understand the timecourse of changes 
of Runx2 and Opn expression for further elucidation of the mechanism. 
 In the in vivo experiments, the cellular level analysis of ectopic osteoid 
formation was performed. It has been shown that bone marrow-derived cells that have 
osteogenic potential, named as marrow-derived osteogenic progenitor cells (MOPC), 
are recruited from the blood circulation into the implantation site of BMP-2 
incorporated carrier material [29-31]. In this study, Sca-1 was used as a marker for 
endothelial/stromal lineage cells. It has been reported that the anti-Sca-1 antibody 
detects some endothelial cells and non-hematopoietic, non-endothelial stromal cells in 
the bone marrow [22, 24]. It is possible that Sca-1 marks endothelial/stromal lineage 
cells in the ectopic site of osteogenesis just as in the bone marrow. The primitive 
mesenchymal cells in non-hematopoietic tissues were initially referred to as CFU-F, 
because they adhered to culture dishes and formed fibroblast-like colonies [32, 33]. 
Primary CFU-F assay has been recently used to quantitate the numbers of mesenchymal 
stromal cells (MSC) in the bone marrow [23]. CFU-F colonies were identified in the 
cells isolated from the subcutaneous tissue implanted with gelatin sponges incorporating 
BMP2, indicating that CFU-Fs may be an index of a primitive mesenchymal cells 
migrated into the site of ectopic bone formation. In this study, the number of CFU-Fs 
decreased with age. It is uncertain whether such a decrease in the number of CFU-Fs is 
cause or result of age-dependent decrease in the activity of ectopic bone formation. 
Even so it is possible that further research on the biological contribution of cells 
infiltrated into the site of bone formation can be feedbacked to the design and 
fabrication of novel scaffolds for bone tissue engineering. 
There are several treatments for bone defects which are caused by resection of 
malignant bone tumors, traumatic injury, and congenital anomaly; implantation of 
bioceramics or autogenous and allogenous bone grafts. Although such treatments are 
extremely popular, there are some risks of the shortage of donor supply, the persistence 
of pain, the nerve damage, fracture, and cosmetic disability at the donor site with 
autografts, disease transmission and immunological reaction with allografts [34, 35]. In 
addition, the potential of bone regeneration decreases with age in human. Bone tissue 
engineering may thus be another choice for the treatment of bone defects to resolve the 
problems [36-38]. A combination of multiple osteoinductive agents and biodegradable 
scaffolds may provide an appropriate osteoinductive environment for osteogenic cells 
even in the patients with decreased osteogenic potential. In the present work, as one 
initial trial, an ectopic bone formation model was applied to evaluate the effect of 
BMP2 and WISP1 dual release on the bone regeneration. Further investigation is 
required to determine whether or not the dual release approach is feasible with different 
animal models considering the clinical treatment of human bone defects. 
   
Conclusion 
We investigated the potential of gelatin sponges incorporating BMP2 and WISP1 in the 
induction of bone formation for middle-aged mice with a decreased osteogenic potential. 
Ectopic osteoid formation was synergistically enhanced by the combined WISP1 and 
BMP2 incorporated in gelatin sponges. This indicates that WISP1 enhanced the effect of 
BMP2-induced osteogenesis through the migration of mesenchymal cells into the site of 
osteoid formation. It is, therefore, concluded that combination of biodegradable cell  
scaffold and dual release of osteogenic agents, such as BMP2 and WISP1, have  
therapeutic potential for patients with decreased ability of bone formation. 
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